Sector News

Janssen/MeiraGTx showcase nine-month data for sight loss gene therapy

October 5, 2020
Life sciences

MeiraGTx and Janssen Pharmaceuticals have announced nine-month data from the ongoing phase I/II trial of their investigational gene therapy for X-linked retinitis pigmentosa (XLRP).

XLRP is a progressive condition that causes deterioration of the visual field and is the most severe form of retinitis pigmentosa – a group of inherited retinal diseases. The most frequent cause of XLRP is disease-causing variants in the RPGR gene, accounting for more than 70% of XLRP cases.

In nine-month data from the phase I/II trial, MeiraGTx and Janssen’s investigational gene therapy AAV-RPGR continued to demonstrate significant improvement in retinal sensitivity in treated eyes, across both the low and intermediate dose cohorts.

In addition, data from the assessment of vision-guided mobility carried out at the nine-month timepoint demonstrated a significant improvement in walk time, compared to baseline in treated eyes compared to untreated eyes in the low and intermediate dose cohorts.

“There are currently no treatment options for XLRP, and vision in patients suffering from this disease inevitably declines over time,” said Michel Michaelides, trial investigator, consultant pphthalmologist, Moorfields Eye Hospital and professor of Ophthalmology, University College London.

“Data from this clinical trial demonstrate that patients treated with AAV-RPGR had significant and sustained improvement in retinal sensitivity, as well as improved ability to navigate in low light conditions. These exciting results continue to suggest that AAV-RPGR has the potential to be a much-needed and important treatment option for those living with XLRP,” he added.

MeiraGTx and Janssen are jointly developing AAV-RPGR as part of a wider collaboration to develop and commercialise gene therapies for the treatment of inherited retinal diseases.

By: Lucy Parsons

Source: Pharma Times

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend